Meningitis Diagnostic Testing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2021 - 2029

The Meningitis Diagnostic Testing Market size is estimated at USD 107.89 million in 2024, and is expected to reach USD 132.73 million by 2029, growing at a CAGR of 4.23% during the forecast period (2024-2029).

Key Highlights

• The COVID-19 pandemic had a significant impact on the meningitis diagnostics testing market. Due to the unavailability of primary care or self-isolation requirements, many people had difficulty getting routine immunizations during the pandemic. For example, a research study published in Clinical Epidemiology and Global Health in February 2022 reported a meningitis outbreak in the Democratic Republic of Congo (DRC) during the pandemic, adding to the strain on healthcare systems. The same source reported a high case fatality rate of 50% for the meningitis outbreak in the DRC.
• As a result, the market experienced moderate growth during the pandemic, as demand for regular immunization vaccines like meningitis and influenza decreased, and the demand for COVID-19 vaccines increased. However, as COVID-19 restrictions ease and cases decrease, people have started opting for regular immunization vaccines for various other diseases, leading to market traction. This trend is expected to continue upward over the forecast period.
• The rising global prevalence of meningitis and increased demand for advanced diagnostics are the primary drivers of the market. Additionally, the growing demand for point-of-care diagnostic services and increasing research and development investments for effective diagnosis and treatment are expected to drive the global meningitis diagnostic testing market over the forecast period.
• For instance, a research study published by NCBI in December 2021 reported the global prevalence of confirmed bacterial meningitis ranged from 0.5% to 61.8% in the pediatric population (0-14 years) and was prevalent in patients of all ages (0-75 years), with a prevalence ranging from 8.7% to 78.9%. The same study indicated that meningitis remains a highly feared disease with a high case fatality rate and the potential to cause epidemics that significantly threaten health systems, economies, and society. Thus, the increasing prevalence of meningitis is expected to drive the adoption of meningitis diagnostic testing, thereby boosting market growth over the forecast period.
• Furthermore, increased government participation in controlling meningitis outbreaks and a rise in the demand for immediate diagnosis systems are expected to contribute to market growth. The World Health Organization (WHO) and global partners and experts involved in meningitis prevention and control developed a global roadmap that sets forth a vision and roadmap to defeat meningitis by 2030.
• This initiative involves multidisciplinary, iterative, and comprehensive consultations with hundreds of experts, Member States representatives, partners civil society organizations, and private sector representatives. Such initiatives will help increase awareness regarding early diagnosis of meningitis, boosting market growth. In addition, increasing research work related to meningitis and its treatment may also drive market growth.
• For example, a study published by Lancet in May 2021 reported that cerebrospinal fluid adenosine deaminase levels (10 IU/L) were strongly associated with bacterial and tubercular meningitis, a central nervous system infection. Therefore, this biomarker might help diagnose tubercular meningitis. Such increasing usage of biomarkers, along with companion diagnostic tests, may have a positive impact on market growth in the coming years.
• However, stringent regulatory policies may hamper market growth over the forecast period.

Meningitis Diagnostic Testing Market Trends

PCR Assay Tests Segment is Expected to Witness Considerable Growth Over the Forecast Period

• The segment of PCR assay tests is expected to hold a significant market share in the meningitis diagnostic testing market, owing to their high precision and accuracy in delivering test results in a short time compared to conventional tests, along with the highest sensitivity rate.
• For instance, a research study published in the PLOS One Journal in March 2022 revealed that the implementation of the FilmArray ME panel was relatively simple, and a change in workflow processes enabled the researcher to streamline cerebrospinal fluid diagnostics and safely remove gram staining from samples tested by this molecular assay. This improvement, along with the rapid turnaround time for results, had a positive clinical impact on patient care. These technological advancements in the products are expected to drive the growth of the PCR assay tests segment over the forecast period.
• Furthermore, the growth of the PCR assay tests segment is expected to be boosted by product launches by key market players to expand their product portfolio. For example, in January 2022, QIAGEN N.V. reported enhancements in the commercialization of its QIAstat-Dx syndromic testing solution, enabling laboratories and hospitals worldwide to test patients for multiple pathogens from one sample, with new tests and the launch of a higher-throughput version that includes a new level of walk-away efficiency through the new QIAstat-Dx Smart Drawer.
• New tests for QIAstat-Dx syndromic solution can distinguish between gastrointestinal pathogens and between meningitis and encephalitis infections. Therefore, owing to the advantages of PCR assay tests and product launches by key players, significant segment growth is anticipated over the forecast period.

North America is Expected to Witness Significant Growth Over the Forecast Period

• North America is anticipated to witness significant growth over the forecast period, driven by several factors, such as the high adoption rate of advanced diagnostic devices, an increased number of diagnostic centers, and the easy availability of diagnostic test kits. For instance, the Centers for Disease Control and Prevention (CDC) issued an outbreak notice in April 2021, stating that Florida was experiencing a significant and ongoing outbreak of meningococcal disease, particularly among gay and bisexual men, including HIV-positive men. This outbreak occurred at the same time when the CDC reported a significant increase in sexually transmitted diseases (STDs), such as gonorrhea, syphilis, and congenital syphilis. The high prevalence of infectious diseases is projected to drive North America's meningitis diagnostic testing market over the forecast period.
• The growth of the meningitis diagnostic testing market in the United States is driven by several factors, including key product launches, a high concentration of market players or manufacturers' presence, acquisition and partnerships among major players, and increasing cases of meningitis. For instance, according to a CDC report in June 2021, approximately 375 cases of meningococcal disease were reported in the United States, with an incidence rate of 0.11 cases per 100,000 persons.
• Additionally, the Meningitis Foundation of America (MFA), a non-profit organization in the United States, provides information and support to individuals who have had personal experiences with meningitis. This foundation is also involved in creating awareness in the public and the medical community about the initial symptoms of meningitis. Therefore, owing to the increasing cases of meningitis, the demand for meningitis diagnostic testing is expected to increase, thereby propelling the market growth over the forecast period in the country.

Meningitis Diagnostic Testing Industry Overview

The meningitis diagnostic testing market is fragmented and consists of several major players. A few of the major players are currently dominating the market in terms of market share. Some prominent players are vigorously making acquisitions with other companies to consolidate their market positions across the globe and while others are launching new products. Some of the companies which are currently dominating the market are Seegene Inc., Siemens Healthineers, IMMY, Thermo Fisher Scientific Inc, and BioFire Diagnostics LLC (BioMérieux), among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

This product will be delivered within 2 business days.